International Journal of Molecular Sciences (Mar 2014)
Correction: Kikuchi, K., et al., Potential of the Angiotensin Receptor Blockers (ARBs) Telmisartan, Irbesartan, and Candesartan for Inhibiting the HMGB1/RAGE Axis in Prevention and Acute Treatment of Stroke. Int. J. Mol. Sci. 2013, 14, 18899–18924.
Abstract
The original version of the paper [1] reports that “This ACTIVE I study was supported by Pfizer” (Page 18905). However, the sponsors of the ACTIVE I study were actually Bristol-Myers Squibb and Sanofi-Aventis rather than Pfizer.
Keywords